These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23762423)

  • 1. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
    Yin H; Park SY; Wang XJ; Misawa R; Grossman EJ; Tao J; Zhong R; Witkowski P; Bell GI; Chong AS
    PLoS One; 2013; 8(6):e65777. PubMed ID: 23762423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
    Kawashima S; Matsuoka TA; Kaneto H; Tochino Y; Kato K; Yamamoto K; Yamamoto T; Matsuhisa M; Shimomura I
    Biochem Biophys Res Commun; 2011 Jan; 404(1):534-40. PubMed ID: 21144823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2009 Jan; 602(2-3):448-54. PubMed ID: 19038243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
    Triplitt C; Cersosimo E; DeFronzo RA
    Vasc Health Risk Manag; 2010 Sep; 6():671-90. PubMed ID: 20859539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
    Jensterle M; Goricar K; Janez A
    Endocr Res; 2017 Nov; 42(4):261-268. PubMed ID: 28323503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
    Cummings BP; Bettaieb A; Graham JL; Stanhope K; Haj FG; Havel PJ
    J Endocrinol; 2014 Apr; 221(1):133-44. PubMed ID: 24627447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
    Cai Y; Lydic TA; Turkette T; Reid GE; Olson LK
    Biochem Pharmacol; 2015 May; 95(1):46-57. PubMed ID: 25801003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
    Moritoh Y; Takeuchi K; Hazama M
    Diabetes Obes Metab; 2010 Mar; 12(3):224-33. PubMed ID: 20151999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-obese Diabetic Mice.
    Maganti AV; Tersey SA; Syed F; Nelson JB; Colvin SC; Maier B; Mirmira RG
    J Biol Chem; 2016 Oct; 291(43):22524-22533. PubMed ID: 27613867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes.
    Tomlinson B; Chan P; Lam CWK
    Expert Opin Pharmacother; 2022 Jan; 23(1):29-42. PubMed ID: 34591742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
    Keating GM
    Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
    Eliasson B; Möller-Goede D; Eeg-Olofsson K; Wilson C; Cederholm J; Fleck P; Diamant M; Taskinen MR; Smith U
    Diabetologia; 2012 Apr; 55(4):915-25. PubMed ID: 22237690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A compounding agent of alogliptin and pioglitazone].
    Ueki K
    Nihon Rinsho; 2011 May; 69(5):877-82. PubMed ID: 21595275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
    Hirukawa H; Kaneto H; Shimoda M; Kimura T; Okauchi S; Obata A; Kohara K; Hamamoto S; Tawaramoto K; Hashiramoto M; Kaku K
    Mol Cell Endocrinol; 2015 Sep; 413():49-60. PubMed ID: 26116826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
    Amano Y; Tsuchiya S; Imai M; Tohyama K; Matsukawa J; Isono O; Yasuno H; Enya K; Koumura E; Nagabukuro H
    Biochem Biophys Res Commun; 2018 Feb; 497(1):207-213. PubMed ID: 29428719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo monitoring of pancreatic beta-cells in a transgenic mouse model.
    Smith SJ; Zhang H; Clermont AO; Powers AC; Kaufman DB; Purchio AF; West DB
    Mol Imaging; 2006; 5(2):65-75. PubMed ID: 16954020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.
    Kono T; Ahn G; Moss DR; Gann L; Zarain-Herzberg A; Nishiki Y; Fueger PT; Ogihara T; Evans-Molina C
    Mol Endocrinol; 2012 Feb; 26(2):257-71. PubMed ID: 22240811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.